PSivida wins court OK to become a U.S. firm

By Mass High Tech Staff

ACT readies for IND of stem-cell-based eye therapy [March 12, 2009]

PSivida posts positive results from eye implant study [March 12, 2009]

Biopure is running out of cash, seeks options [February 17, 2009]

Nasdaq gives Biopure a break from enforcing trading compliance [December 31, 2008]

Drug delivery firm pSivida Ltd. of Australia says it has won court approval of its plan to reincorporate as a U.S. company.

PSivida (Nasdaq: PSDV) (ASX: PSD) (FSE: PSI), which has a local office in Watertown, reports that the Federal Court of Australia approved the reincorporating plan, and the scheme is due to become effective June 11.

The firm’s shares will cease trading on the Australian Securities Exchange at the close of trading June 11, and its stock is expected to commence trading on the Nasdaq and Frankfurt stock exchanges on June 11 or June 12 for Nasdaq and June 12 for Frankfurt, according to the company.

The life sciences company is a global provider of nano-structured silicon, called BioSilicon, intended for use in the drug delivery, orthopedics, wound healing and tissue engineering markets. It also licenses drug delivery technology for two products approved by the U.S. Food and Drug Administration.

With 26 employees, pSivida reported a 2007 net loss of $94.4 million on revenue of $2.5 million.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.